Literature DB >> 12824887

Fatty acid-CoA ligase 4 is overexpressed in human hepatocellular carcinoma.

Young Kwan Sung1, Sun Young Hwang, Mi Kyung Park, Han Ik Bae, Woo Ho Kim, Jung-Chul Kim, Moonkyu Kim.   

Abstract

Fatty acid-CoA ligase 4 (FACL4) is a central enzyme controlling the unesterified arachidonic acid (AA) level in cells. It has been shown that FACL4 blocks apoptosis and promotes colon carcinogenesis by lowering the cellular level of unesterified AA. Consistent with this, FACL4 is upregulated in colon adenocarcinoma. The status of FACL4 in other tumors including hepatocellular carcinoma (HCC) is not known. Here, we report that FACL4 is overexpressed in human HCC compared with adjacent normal liver tissues. FACL4 mRNA and protein were overexpressed in 5 out of 12 (41.7%) and 3 out of 8 (37.5%) cases of HCC, respectively. Immunohistochemical staining showed strong fine granular intracytoplasmic staining in tumor cells, whereas we observed occasional weak staining in normal liver tissues surrounding the tumors. We found that 14 out of 37 (37.8%) HCC expressed moderate to strong FACL4 immunostaining. Both normal adult and fetal liver tissues showed very weak to no detectable staining, whereas 3 out of 10 (30%) cirrhotic livers expressed weak staining. In addition, we found that 4 out of 8 (50%) human hepatoma cell lines expressed high levels of FACL4 by northern blot analysis. Our results show that FACL4 is a new molecular marker for HCC and suggest that the FACL4 pathway may be involved in liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824887     DOI: 10.1111/j.1349-7006.2003.tb01458.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  29 in total

1.  Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Authors:  M D Landis; D D Seachrist; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

2.  New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis.

Authors:  Ana F Castillo; Ulises D Orlando; Paula M Maloberti; Jesica G Prada; Melina A Dattilo; Angela R Solano; María M Bigi; Mayra A Ríos Medrano; María T Torres; Sebastián Indo; Graciela Caroca; Hector R Contreras; Belkis E Marelli; Facundo J Salinas; Natalia R Salvetti; Hugo H Ortega; Pablo Lorenzano Menna; Sergio Szajnman; Daniel E Gomez; Juan B Rodríguez; Ernesto J Podesta
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

Review 3.  Acyl-CoA metabolism and partitioning.

Authors:  Trisha J Grevengoed; Eric L Klett; Rosalind A Coleman
Journal:  Annu Rev Nutr       Date:  2014-04-10       Impact factor: 11.848

4.  Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity.

Authors:  Marie E Monaco; Chad J Creighton; Peng Lee; Xuanyi Zou; Matthew K Topham; Diana M Stafforini
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

5.  Tyrosine phosphatase SHP2 regulates the expression of acyl-CoA synthetase ACSL4.

Authors:  Mariana Cooke; Ulises Orlando; Paula Maloberti; Ernesto J Podestá; Fabiana Cornejo Maciel
Journal:  J Lipid Res       Date:  2011-09-08       Impact factor: 5.922

6.  Liver-specific knockdown of long-chain acyl-CoA synthetase 4 reveals its key role in VLDL-TG metabolism and phospholipid synthesis in mice fed a high-fat diet.

Authors:  Amar B Singh; Chin Fung K Kan; Fredric B Kraemer; Raymond A Sobel; Jingwen Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-02-05       Impact factor: 4.310

7.  Long-chain acyl-CoA synthetase 4 modulates prostaglandin E₂ release from human arterial smooth muscle cells.

Authors:  Deidre L Golej; Bardia Askari; Farah Kramer; Shelley Barnhart; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Karin E Bornfeldt
Journal:  J Lipid Res       Date:  2011-01-17       Impact factor: 5.922

8.  Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells.

Authors:  Paula M Maloberti; Alejandra B Duarte; Ulises D Orlando; María E Pasqualini; Angela R Solano; Carlos López-Otín; Ernesto J Podestá
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

Review 9.  Fatty acid activation in carcinogenesis and cancer development: Essential roles of long-chain acyl-CoA synthetases.

Authors:  Yue Tang; Jing Zhou; Shing Chuan Hooi; Yue-Ming Jiang; Guo-Dong Lu
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

10.  The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.

Authors:  Ulises D Orlando; Juan Garona; Giselle V Ripoll; Paula M Maloberti; Ángela R Solano; Alejandra Avagnina; Daniel E Gomez; Daniel F Alonso; Ernesto J Podestá
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.